Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe

Дата публикации: 16-06-2026 10:01:37

The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton	0	23.7	03-04-2026
2	FDA Grants Orphan Drug Designation to Once-Nightly Oxybate for Idiopathic Hypersomnia	0	10.68	16-07-2026
3	FDA Approves First Orexin-Targeting Drug for Narcolepsy Type 1	0	18.04	05-08-2026
4	Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy	0	13.43	25-07-2026
5	New Pivotal Study Data Released for Takeda’s Oveporexton	5	7	16-06-2026
6	Lundbeck Receives FDA Fast Track Designation for Lu AH69593, an Investigational Orexin 2 Receptor Agonist for Narcolepsy	0	13.22	23-07-2026
7	Orzeyful improves wakefulness, reduces cataplexy in narcolepsy	0	11.1	07-08-2026
8	Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments	2	6	24-06-2026
9	Incannex Secures US Patent for Sleep Apnea Drug Candidate IHL-42X	5	7	16-07-2026
10	Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders	0	14.65	31-03-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: sleepreviewmag.com.